Great Lakes Advisors LLC Trims Holdings in Boston Scientific Corporation $BSX

Great Lakes Advisors LLC lessened its holdings in Boston Scientific Corporation (NYSE:BSX) by 1.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,834,401 shares of the medical equipment provider’s stock after selling 25,464 shares during the quarter. Boston Scientific accounts for 1.5% of Great Lakes Advisors LLC’s investment portfolio, making the stock its 10th biggest position. Great Lakes Advisors LLC’s holdings in Boston Scientific were worth $179,093,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares during the period. Sound Income Strategies LLC increased its stake in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares during the period. Venture Visionary Partners LLC lifted its position in Boston Scientific by 110.0% in the second quarter. Venture Visionary Partners LLC now owns 12,551 shares of the medical equipment provider’s stock valued at $1,348,000 after purchasing an additional 6,575 shares during the last quarter. Janney Montgomery Scott LLC boosted its stake in shares of Boston Scientific by 4.4% during the second quarter. Janney Montgomery Scott LLC now owns 297,960 shares of the medical equipment provider’s stock valued at $32,004,000 after purchasing an additional 12,497 shares during the period. Finally, HB Wealth Management LLC grew its holdings in shares of Boston Scientific by 16.8% in the second quarter. HB Wealth Management LLC now owns 45,261 shares of the medical equipment provider’s stock worth $4,861,000 after purchasing an additional 6,502 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In other news, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director owned 24,134 shares in the company, valued at $2,371,889.52. This trade represents a 34.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 80,204 shares of company stock valued at $7,998,563. 0.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on BSX shares. BTIG Research reiterated a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a report on Friday, November 21st. Erste Group Bank cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Truist Financial dropped their target price on shares of Boston Scientific from $130.00 to $120.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Needham & Company LLC reissued a “buy” rating on shares of Boston Scientific in a research note on Thursday, January 15th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $123.89.

Boston Scientific Trading Up 0.1%

Shares of BSX opened at $93.74 on Thursday. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The firm’s 50-day moving average price is $95.36 and its 200-day moving average price is $99.65. The firm has a market capitalization of $138.96 billion, a price-to-earnings ratio of 50.13, a PEG ratio of 1.66 and a beta of 0.67.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.